



MULTI-STAKEHOLDER WORKSHOP

Health Technology Assessment
in cancer drug development

5 - 6 October 2026
Brussels, Belgium
Hybrid Workshop



www.cddf.org

EVENT OUTLINE

This multi-stakeholder workshop will explore the dynamic Health Technology Assessment (HTA) environment in Europe and its critical impact on cancer care. The event will bring together experts from regulatory agencies, HTA bodies, pharmaceutical industry, academia, healthcare providers, and patient advocacy groups to examine how scientific innovation, healthcare sustainability, patient access, transparency, equity, and societal expectations are reshaping HTA decision-making.

Participants will delve into the practical implications of Regulation (EU) 2021/2282 and Joint Clinical Assessments, while analyzing the methodological foundations that underpin HTA processes. The workshop will provide actionable insights on integrating HTA considerations earlier in drug development and assess how HTA systems can adapt to future innovations in precision medicine, advanced therapies, AI, and digital health.

The 1.5-day meeting consists of 4 plenary sessions, interactive panel discussions, and dedicated time for multi-stakeholder dialogue and networking. Each session is designed to foster cross-disciplinary understanding and practical application of HTA principles in oncology.

LEARNING OBJECTIVES

By the end of the meeting, participants will be able to:

- **Describe the evolving Health Technology Assessment (HTA) landscape** in Europe and explain how scientific innovation, healthcare system sustainability, patient access, transparency, equity, and societal expectations are shaping HTA decision-making in cancer care.
- **Explain the practical implications of Regulation (EU) 2021/2282 and Joint Clinical Assessments for oncology medicines**, including emerging implementation challenges, opportunities to reduce duplication, and the need for methodological consistency and alignment with national decision-making processes.
- **Analyse the methodological foundations of HTA**, including assessment scope, comparator selection, outcomes, patient subgroups, evidence maturity, indirect comparisons, uncertainty, added value, and the appropriate use of real-world evidence.
- **Apply HTA considerations earlier in cancer drug development** by identifying how trial design, endpoint selection, evidence generation strategies, regulatory interactions, and access planning can better address the needs of clinicians, patients, HTA bodies, payers, and national decision-makers.
- **Assess how HTA systems can adapt to future innovation in oncology**, including precision medicine, advanced therapy medicinal products, artificial intelligence, digital health tools, real-world data infrastructures, and adaptive evidence-generation models, while supporting timely, equitable, and sustainable patient access.

PROGRAMME COMMITTEE

- Programme chair: Rosa Giuliani (CDDF, UK)
- Programme co-chair: Denis Lacombe (EORTC, BE)
- Sacha Wissink (MSD, NL)
- Maddalena Malerba (BMS, CH)

TARGET AUDIENCE

The target is a multidisciplinary audience of academia representatives, EU and US regulatory bodies (EMA, FDA, National Agencies), pharmaceutical Industry, HTAs and patient advocate.

WORKSHOP VENUE

Cardo Brussels
Av. du Boulevard 14, 1210 Brussels

HYBRID WORKSHOP

The workshop will be held in Brussels. However, participation online via the Brella event platform will also be possible. Only approved participants will receive the link and log-in details to access the virtual platform.

CONTACT

Cancer Drug Development Forum (CDDF)
Email: giorgia@cddf.org, info@cddf.org
Website: www.cddf.org
Address: c/o BLSI Clos Chapelle-aux-Champs 30, 1200 Brussels, Belgium

PROGRAMME

Day 1 : Monday, 5 October 2026

SESSION 1: SETTING THE SCENE: HTA LANDSCAPE AND SOCIETAL NEEDS

Session Chairs: Denis Lacombe (EORTC, BE); Gerry Feeney (Patient Advocate, UK)

12:00 - 12:50	Lunch
12:50 - 13:00	Welcome note Rosa Giuliani (CDDF, UK) & Denis Lacombe (EORTC, BE)
13:00 - 13:15	HTA Landscape Roisin Adams (NCPE, IE)
13:15 - 13:30	Payers' Perspective Yannis Natsis (ESIP; MEDEV, BE)
13:30 - 13:45	Clinician's Perspective Gabe Sonke (Netherlands Cancer Institute, NL)
13:45 - 14:25	Panel Discussion Guest Panelists: Lara Wolfson (MSD, BE)
14:25 - 14:55	Coffee Break

SESSION 2: IMPLEMENTATION OF HTA REGULATION: PRACTICAL LEARNINGS

Session Chairs: Maddalena Malerba (BMS, CH); Beate Wieseler (IQWiG, DE)

14:55 - 15:00	Session opening
15:00 - 15:15	The Regulation and Its Implementation, Lessons Learned Maya Matthews (European Commission, BE)

15:15 - 15:30	Collaborative Industry Perspective Maria Nieto-Gutierrez (AstraZeneca, UK)
15:30 - 15:45	HTA perspective on implementing the EU assessment Beate Wieseler (IQWiG, DE)
15:45 - 16:25	Panel Discussion Guest Panelists: • Carole Longson (Carole Longson Consultancy, UK) • Josephine Mosset (Cancer Patients Europe, BE) • Mojca Unk (Institute of Oncology Ljubljana, SI)
16:25 - 16:45	Coffee break
SESSION 3: HTA REGULATION AND METHODOLOGICAL FOUNDATIONS	
Session Chairs: Sacha Wissink (MSD, NL); Oriol Solà Morales (Fundació HiTT, ES)	
16:45 - 16:50	Session opening
16:50 - 17:05	Overview of HTA Regulation Principles (Methodology) Sara Couto (National Authority of Medicines and Health Products, PT)
17:05 - 17:20	Bridging Regulatory and HTA Frameworks: Estimands, PICO, and Meaningful Endpoints Kristel Vandormael (MSD, BE)
17:20 - 17:35	Bridging the Evidence Gap for EU Joint Clinical Assessments Oriol Solà Morales (Fundació HiTT, ES)
17:35 - 18:15	Panel Discussion Guest Panelist: • Aris Angelis (Chair, Greek HTA Committee and Advisor to the Minister of Health; CHMP Member, European Medicines Agency; Visiting Associate Professor, London School of Hygiene & Tropical Medicine, GR)
18:30 - 19:30	CDDF Leadership and Industry Panel Meeting (internal meeting)
19:30 - 22:00	Offsite dinner (Serra Restaurant) CDDF 25 Years Celebration with speech by John Smyth

Day 2 : Tuesday, 6 October 2026

SESSION 4: LOOKING AHEAD: PREPARING FOR FUTURE INNOVATION

Session Chairs: Rosa Giuliani (CDDF, IT); Anja Schiel (Norwegian Medicines Agency, NO)

08:00 - 10:00	CDDF Board of Directors meeting (internal meeting)
10:15 - 10:20	Session opening
10:20 - 10:35	Horizon Scanning Activities Enrico Tognana (European Medicines Agency, NL)
10:35 - 10:50	Emerging Health Technologies Kim Helleberg Madsen (Danish Medicines Agency, DK)
10:50 - 11:05	Patient Perspective Solène Jouan (European Patients' Forum, BE)
11:05 - 11:20	Navigating Policy Evolution: Now and Future Anja Schiel (Norwegian Medicines Agency, NO)
11:20 - 12:10	Panel Discussion Guest Panelists: - Piotr Rutkowski (Maria Skłodowska-Curie National Research Institute of Oncology, PO) - James Ryan (AstraZeneca, UK) - Rachel Giles (VHL Europa, NL)

SESSION 5: WORKSHOP WRAP-UP AND NEXT STEPS

Session Chairs: Rosa Giuliani (CDDF, IT); Denis Lacombe (EORTC, BE)

12:10 - 12:30	Wrap up panel discussion Panelists: Programme Committee
12:30 - 12:35	Farewell Message
12:35 - 13:30	Lunch and Departure